Author

Luke Hickey

Observed institutions: Jazz Pharmaceuticals (United States), Jazz Pharmaceuticals (Ireland)

ORCID: 0000-0002-8691-9936

Observed ORCID: 0000-0002-8691-9936

OpenAlex ID: A5049600568

Efficacy and Safety of Lower-Sodium Oxybate in an Open-Label Titration Period of a Phase 3 Clinical Study in Adults with Idiopathic Hypersomnia

2022 · Michael J Thorpy, Isabelle Arnulf, et al. · Nature and Science of Sleep · 20

Long-term efficacy and safety of low-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia

2023 · Anne Marie Morse, Yves Dauvilliers, et al. · Journal of Clinical Sleep Medicine · 16

0393 Weight Changes During Treatment With Lower-Sodium Oxybate in a Phase 3 Clinical Study in Patients With Narcolepsy

2022 · Nancy Foldvary-Schaefer, Roman Skowronski, et al. · SLEEP · 3

0387 Weight Changes During Treatment With Lower-Sodium Oxybate in a Phase 3 Clinical Study in Patients With Idiopathic Hypersomnia

2022 · Yves Dauvilliers, Patricia Chandler, et al. · SLEEP · 2

Psychometric Evaluation of the Idiopathic Hypersomnia Severity Scale (P1-7.001)

2022 · Benjamin Banderas, Susan Morris, et al. · Neurology · 1

Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis

2026 · Tuan Vu, Stojan Peric, et al. · Neurology

Long-Term Effects of Lower-Sodium Oxybate on Functioning and Work Productivity in Participants With Idiopathic Hypersomnia (P1-7.003)

2022 · Richard K. Bogan, Isabelle Arnulf, et al. · Neurology

Long-Term Efficacy and Safety of Lower-Sodium Oxybate in a Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Adults With Idiopathic Hypersomnia (P1-7.004)

2022 · Nancy Foldvary-Schaefer, Richard K. Bogan, et al. · Neurology

Works count: 8

Citation count: 42

H-index: 3

I10-index: 2